Witness to progress

Circulation: Heart Failure

Volumn 4, Issue 4, 2011, Pages 390-392

  Stevenson, Lynne Warner ^a   Pande, Reena ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Editorials; Heart failure; Morbidity; Mortality

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; LOOP DIURETIC AGENT; NITROPRUSSIDE SODIUM;

CARDIAC RESYNCHRONIZATION THERAPY DEVICE; DEFIBRILLATOR; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; HYPERKALEMIA; MORTALITY; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; CARDIAC RESYNCHRONIZATION THERAPY; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; NOTE; SURVIVAL RATE; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; CARDIAC RESYNCHRONIZATION THERAPY; DEATH, SUDDEN, CARDIAC; GREAT BRITAIN; HEART FAILURE; HUMANS; MIDDLE AGED; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80052802618     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.963066     Document Type: Review

References (19)

1. MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000;102:1126-1131.
2. Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. Eur Heart J. 2009;30:671-678..
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-1402. (Pubitemid 35239711)
4. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. (Pubitemid 44079340)
5. Cubbon RM, Gale CP, Kearney LC, Schechter CB, Brooksby WP, Nolan J, Fox KA, Rajwani A, Baig W, Groves D, Barlow P, Fisher AC, Batin PD, Kahn MB, Zaman AG, Shah AM, Byrne JA, Lindsay SJ, Sapsford RJ, Wheatcroft SB, Witte KK, Kearney MT. Changing characteristics and mode of death associated with chronic heart failure due to left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Failure. 2011;4:396-403.
6. Pande RL, Teuteberg JJ, Tsang S, Lewis E, Nohria A, Fang J, Givertz M, Jarcho J, Mudge GH, Baughman KL, Stevenson LW. Improved survival for class III heart failure after 2000: impact of therapies demonstrated in a real-life population [abstract]. Circulation. 2006;114:II-573.
7. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation. 1985;72:681-685. (Pubitemid 16245173)
8. Arshad A, Mandava A, Kamath G, Musat D. Sudden cardiac death and the role of medical therapy. Prog Cardiovasc Dis. 2008;50:420-438. (Pubitemid 351649368)
9. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551. (Pubitemid 39025171)
10. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
11. ESCAPE Investigators and Coordinators. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization. JAMA. 2005;294: 1625-1633.
12. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, Tillisch JH, Walden JA, Albanese E. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19:842-850.
13. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549. (Pubitemid 40517094)
14. Cleland JG, Charlesworth A, Lubsen J, Swedberg K, Remme WJ, Erhardt L, Di Lenarda A, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson PA. A comparison of the effects of carvedilol and metoprolol on wellbeing, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol. 2006;47:1603-1611.
15. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361: 1843-1848. (Pubitemid 36645177)
16. Punnoose LR, Pratibhu P, Givertz M, Lewis E, Stevenson LW, Desai A. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail. 2011; published online April 29, 2011.
17. Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, Walton A, Adamson P, Kar S, Shah PK, Richards M, Eigler NL, Whiting JS, Haas GJ, Heywood JT, Frampton CM, Abraham WT. Physiciandirected patient self-management of left atrial pressure in advanced chronic heart failure. Circulation. 2010;121:1086-1095.
18. Setoguchi S, Nohria A, Rassen JA, Stevenson LW, Schneeweiss S. Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure. Can Med Assoc J. 2009;180:611-616.
19. Setoguchi S, Glynn RJ, Stedman M, Flavell CM, Levin R, Stevenson LW. Hospice, opiates, and acute care service use among the elderly before death from heart failure or cancer. Am Heart J. 2010;160:139-144.